Background: To assess the incidence rate and prevalence ratio of multiple sclerosis (MS) in Austria. Methods: Hospital discharge diagnosis and MS-specific immunomodulatory treatment prescriptions from public health insurances, covering 98% of Austrian citizens with health insurance were used to extrapolate incidence and prevalence numbers based on the capture-recapture method. Results: A total of 1,392,629 medication prescriptions and 40,956 hospitalizations were extracted from 2 data sources, leading to a total of 13,205 patients. The incidence rate and prevalence ratio of MS in Austria based on the capture-recapture method were 19.5/100,000 person-years (95% CI 14.3-24.7) and 158.9/100,000 (95% CI 141.2-175.9), respectively. Female to male ratio was 1.6 for incidence and 2.2 for prevalence. Conclusions: Incidence rates and prevalence ratios of MS in our study are within the upper range of comparable studies across many European countries as well as the United States.

1.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
2.
Prange AJ, Lauer K, Poser S, Palffy G, Minderhoud JM, Firnhaber W, et al: Epidemiological aspects of multiple sclerosis: a comparative study of four centres in Europe. Neuroepidemiology 1986;5:71-79.
3.
Koch-Henriksen N, Magyari M, Laursen B: Registers of multiple sclerosis in Denmark. Acta Neurol Scand 2015;132:4-10.
4.
Baumhackl U, Eibl G, Ganzinger U, Hartung HP, Mamoli B, Pfeiffer KP, et al: Prevalence of multiple sclerosis in Austria. Results of a nationwide survey. Neuroepidemiology 2002;21:226-234.
5.
Baumhackl U: Multiple Sklerose. Prävalenz&Therapie im 12-Jahres-Vergleich in Österreich. Facultas Verlag.
6.
Hook EB, Regal RR: Capture-recapture methods in epidemiology: methods and limitations. Epidemiol Rev 1995;17:243-264.
7.
Cetin H, Rath J, Füzi J, Reichardt B, Fülöp G, Koppi S, et al.: Epidemiology of amyotrophic lateral sclerosis and effect of riluzole on disease course. Neuroepidemiology 2015;44:6-15.
8.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al: Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
9.
Simonsen CS, Edland A, Berg-Hansen P, Celius EG: High prevalence and increasing incidence of multiple sclerosis in the Norwegian county of Buskerud. Acta Neurol Scand 2017;135:412-418.
10.
Bargagli AM, Colais P, Agabiti N, Mayer F, Buttari F, Centonze D, et al: Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems. J Neurol 2016;263:751-759.
11.
Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD: Multiple sclerosis prevalence in the United States commercially insured population. Neurology 2016;86:1014-1021.
12.
Koch-Henriksen N, Sørensen PS: The changing demographic pattern of multiple sclerosis epidemiology. Lancet Neurol 2010;9:520-532.
13.
Midgard R, Riise T, Svanes C, et al: Incidence of multiple sclerosis in Møre and Romsdal, Norway from 1950 to 1991. Brain 1996;119:203-211.
14.
Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F: Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult Scler 2007;13:962-967.
15.
Fasbender P, Kolmel HW: Incidence of multiple sclerosis in the urban area of Erfurt, Thuringia, Germany. Neuroepidemiology 2008;30:147-151.
16.
Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M: Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985-2000. Neurology 2003;61:1373-1377.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.